Szturmowicz M, Sakowicz A, Rudzinski P, Zych J, Wiatr E, Zaleska J, Rowinska-Zakrzewska E
Dept. of Internal Medicine, Institute of Tuberculosis and Lung Diseases, Warsaw, Poland.
Int J Biol Markers. 1996 Jul-Sep;11(3):172-7. doi: 10.1177/172460089601100306.
Cytokeratin-19, one of the cytoskeletal proteins, is expressed both in bronchial epithelium and in lung cancer cells. The aim of our study was to establish the value of serum cytokeratin-19 soluble fragment (Cyfra 21-1) measurement in lung cancer patients. Cyfra 21-1 levels were estimated in 35 patients (pts) with benign lung diseases and in 116 lung cancer patients: 55 pts with squamous cell lung cancer, 38 pts with small cell lung cancer and 23 pts with adenocarcinoma. The cutoff level was set at 4 ng/ml with a specificity of 94% and a sensitivity of 40%. Elevated Cyfra 21-1 values were found in 44% of squamous cell lung cancer, 39% of adenocarcinoma and 34% of small cell lung cancer pts (the difference was not significant). In squamous cell lung cancer and in adenocarcinoma elevated Cyfra 21-1 values were observed more often in patients with advanced disease than in patients with limited disease. There was no significant correlation between the initial Cyfra 21-1 level and the response to chemotherapy. Cyfra 21-1 was not a prognostic indicator, although in operable squamous cell lung cancer the proportion of survivors in the second year of observation was higher among the patients with normal preoperative Cyfra 21-1 levels.
细胞角蛋白-19是一种细胞骨架蛋白，在支气管上皮细胞和肺癌细胞中均有表达。我们研究的目的是确定检测肺癌患者血清细胞角蛋白-19可溶性片段（Cyfra 21-1）的价值。对35例良性肺病患者和116例肺癌患者进行了Cyfra 21-1水平检测：55例鳞状细胞肺癌患者、38例小细胞肺癌患者和23例腺癌患者。临界值设定为4 ng/ml，特异性为94%，敏感性为40%。44%的鳞状细胞肺癌患者、39%的腺癌患者和34%的小细胞肺癌患者Cyfra 21-1值升高（差异无统计学意义）。在鳞状细胞肺癌和腺癌中，病情晚期患者Cyfra 21-1值升高的情况比病情局限患者更常见。初始Cyfra 21-1水平与化疗反应之间无显著相关性。Cyfra 21-1不是一个预后指标，尽管在可手术切除的鳞状细胞肺癌中，术前Cyfra 21-1水平正常的患者在观察的第二年生存率较高。
